Übersetzung für "Cardiac myocytes" in Deutsch

Other cells such as skeletal and cardiac myocytes as well as endothelial cells also produce adiponectin.

Normal cardiac myocytes have a static resting potential.

Cardiac myocytes are much shorter than skeletal muscle cells.

Thus we are analysing if DYRK inhibits maladaptive hypertrophy in cardiac myocytes.

And I think they'll be a new era of your own stem cell banking to have in the freezer your own cardiac cells, myocytes and neural cells to use them in the future, should you need them.

Consistent with the clinical effects of Replagal, treatment with the enzyme reduced accumulation of Gb3 in many cell types, including renal glomerular and tubular epithelial cells, renal capillary endothelial cells (cardiac and dermal capillary endothelial cells were not examined) and cardiac myocytes.

Nicardipine has a greater selectivity for L-type calcium channels in vascular smooth muscle than cardiac myocytes.

Ambrisentan blocks the ETA receptor subtype, localized predominantly on vascular smooth muscle cells and cardiac myocytes.

Adrenaline arrived on the cardiac myocytes, which released too much of their cells' calcium.

Pacemaker cells and normal cardiac myocytes receive synaptic input from the autonomic nervous system, but this neural input modulates, rather than initiates, the generation of action potentials.

After a pre-incubation of the cardiac myocytes with the calcium antagonists, the synthesis of "stress proteins" evoked by a toxin (CdCl2) is significantly reduced while total protein synthesis remains unaffected.

Although millions of cardiac myocytes perish during an infarction: "We need only about 100,000 cells to achieve the positive effects on the cardiac rhythm", says Fleischmann.

Indeed, it could be recently shown by the inventors that BDPs remain their ability to trans-differentiate into functional cardiac myocytes (Badorff C, Brandes R P, Popp R, Rupp S, Urbich C, Aicher A, Fleming I, Busse R, Zeiher AM, Dimmeler S. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes.

The compound according to any one of claims 1 to 6 and/or the pharmaceutical composition according to clam 7 for use in treating a disease or disorder selected from the list consisting of neurodegenerative diseases and disorders, cardiovascular diseases and disorders, Alzheimer?s disease, Parkinson?s disease, cardiac hypertrophy, heart failure, myocardial infarction, ischemia/reperfusion injury, apoptosis, autophagy of cardiac myocytes, atrial fibrillation (AF), and cardiac arrhythmia.

Compound according to any one of claims 1 to 8 for use in treating a disease or disorder selected from the list consisting of neurodegenerative diseases and disorders, cardiovascular diseases and disorders, Alzheimer?s disease, Parkinson?s disease, cardiac hypertrophy, heart failure, myocardial infarction, ischemia/reperfusion injury, apoptosis, autophagy of cardiac myocytes, atrial fibrillation (AF), and cardiac arrhythmia.

Pharmaceutical composition according to claim 9 for use in treating a disease or disorder selected from the list consisting of neurodegenerative diseases and disorders, cardiovascular diseases and disorders, Alzheimer?s disease, Parkinson?s disease, cardiac hypertrophy, heart failure, myocardial infarction, ischemia/reperfusion injury, apoptosis, autophagy of cardiac myocytes, atrial fibrillation (AF), and cardiac arrhythmia.

A method for treating a disease or disorder selected from the list consisting of neurodegenerative diseases and disorders, cardiovascular diseases and disorders, Alzheimer's disease, Parkinson's disease, cardiac hypertrophy, heart failure, myocardial infarction, ischemia/reperfusion injury, apoptosis, autophagy of cardiac myocytes, atrial fibrillation (AF), and cardiac arrhythmia comprising administering to a subject in need thereof a therapeutically effective amount of the compound according to claim 1 .

Exposition of the cultured cardiac myocytes first to the anthracyclines and afterwards to another toxin (CdCl2) causes a significant inhibition of "stress protein" formation indicating that the cells are less resistant to the second damaging influence.

The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hyper-tension or vasoconstriction.

The compounds according to the invention are preferably used for the preparation of a medicament for the treatment of a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infection or inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke, or ischaemic states, cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction.

The compounds of the formula (I) are preferably suitable for the treatment of cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction.

The compounds of the formula I are preferably suitable for the treatment of cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction.

The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction.